• Semnur Pharmaceuticals signed a binding term sheet for a $100 million private placement with iHolding Group LLP.
• iHolding would buy newly issued common stock at an expected price of $10 per share, implying 10,000,000 shares.
• Proceeds would fund the SEMDEXA (SP-102) Phase 3 program, pipeline development, commercialization, acquisitions, partnerships, working capital.
• Transaction remains subject to due diligence, definitive agreements, board approvals, customary closing conditions, regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Semnur Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070600PRIMZONEFULLFEED9757116) on July 07, 2026, and is solely responsible for the information contained therein.